ASPAGNIITM Trademark for SPAG9 recombinant protein: Trade Marks Journal No: 1970, 19/10/2020; class 5; 4589630 30/07/2020, National Institute of Immunology, Aruna Asaf Ali Marg, India.

Proposed to be Used
Cell based immunotherapeutic vaccine component for cancer treatment of various types of cancer; Adjuvants and neo-adjuvants for medical use for the treatment of cancer; Pharmaceutical preparations for the treatment of communicable and non-communicable diseases


Copyright © 2012 National Institute of Immunology. All Rights Reserved.

150 Years of Celebrating The Mahatma